34 results on '"Hegi-Johnson F"'
Search Results
2. MA03.03 Does Smoking Status Affect Survival After Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer?
- Author
-
Wallace, N.D., primary, Alexander, M., additional, Xie, S., additional, Ball, D., additional, Solomon, B., additional, Plumridge, N., additional, Shaw, M., additional, Harden, S., additional, Hegi-Johnson, F., additional, Siva, S., additional, John, T., additional, Officer, A., additional, and MacManus, M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. EP08.02-23 Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC?
- Author
-
MacManus, M.P., primary, Alexander, M., additional, Xie, J., additional, Ball, D., additional, Solomon, B., additional, Plumridge, N., additional, Shaw, M., additional, Harden, S., additional, Hegi-Johnson, F., additional, Siva, S., additional, John, T., additional, Officer, A., additional, and Wallace, N., additional
- Published
- 2023
- Full Text
- View/download PDF
4. P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT doses during chemoRT for NSCLC Correlates with Lymphocyte Decline
- Author
-
MacManus, M.P., primary, Prins, E., additional, Hegi-Johnson, F., additional, Hicks, R., additional, Callahan, J., additional, Akhurst, T., additional, Xie, J., additional, and Everitt, S., additional
- Published
- 2023
- Full Text
- View/download PDF
5. P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT
- Author
-
Hegi-Johnson, F., primary, Rudd, S., additional, Roselt, P., additional, Wichmann, C., additional, Sursock, S., additional, Akhurst, T., additional, Jackson, P., additional, Hicks, R., additional, Scott, A., additional, Donnelly, P., additional, John, T., additional, and MacManus, M., additional
- Published
- 2023
- Full Text
- View/download PDF
6. P1.28-04 Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy?
- Author
-
Wallace, N.D., primary, Alexander, M., additional, Xie, S., additional, Ball, D., additional, Solomon, B., additional, Plumridge, N., additional, Shaw, M., additional, Harden, S., additional, Hegi-Johnson, F., additional, Siva, S., additional, John, T., additional, Officer, A., additional, and MacManus, M., additional
- Published
- 2023
- Full Text
- View/download PDF
7. PD-0971 Radiation dose response of bone marrow during chemoRT for NSCLC measured by serial FLT-PET
- Author
-
Prins, E., primary, MacManus, M., additional, Hegi-Johnson, F., additional, Callahan, J., additional, Xie, J., additional, Hicks, R., additional, Akhurst, T., additional, and Everitt, S., additional
- Published
- 2023
- Full Text
- View/download PDF
8. MO-0473 Lymphopenia during NSCLC ChemoRT is proportional to FLT-detected suppression of irradiated marrow
- Author
-
MacManus, M., primary, Prinz, E., additional, Hegi-Johnson, F., additional, Callahan, J., additional, Hicks, R., additional, Akhurst, T., additional, Xie, S., additional, and Everitt, S., additional
- Published
- 2023
- Full Text
- View/download PDF
9. PD-0970 Biodistribution Data of ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr- Durvalumab
- Author
-
Hegi-Johnson, F., primary, Rudd, S., additional, Roselt, P., additional, Wichmann, C., additional, Callahan, J., additional, Akhurst, T., additional, Jackson, P., additional, Hicks, R., additional, Scott, A., additional, Donnelly, P., additional, John, T., additional, Hanna, G., additional, and MacManus, M., additional
- Published
- 2023
- Full Text
- View/download PDF
10. MA09.05 Increased PD-L1 Tracer Uptake in Recently-irradiated Lesions in NSCLC: Preliminary Results of a Phase 0 Trial (ImmunoPET) of a Novel PET Tracer
- Author
-
Hegi-Johnson, F., primary, Akhurst, T., additional, Rudd, S., additional, Donnelly, P., additional, Scott, A., additional, Callahan, J., additional, Roselt, P., additional, John, T., additional, Sithara, S., additional, Wichmann, C., additional, Hanna, G., additional, and MacManus, M., additional
- Published
- 2022
- Full Text
- View/download PDF
11. P1.10-02 ImmunoPET: A Phase 0/1 Study Characterising PD-L1 with 89Zr-Durvalumab (MEDI4736) PET/CT in Stage III NSCLC Patients Receiving Chemoradiation
- Author
-
MacManus, M., primary, Rudd, S., additional, Roselt, P., additional, Wichmann, C., additional, Callahan, J., additional, John, T., additional, Scott, A., additional, Donnelly, P., additional, Hanna, G., additional, and Hegi-Johnson, F., additional
- Published
- 2022
- Full Text
- View/download PDF
12. P2.03-01 Initial Biodistribution Data of ImmunoPET A Phase 0/1 Study Characterising PD-L1 with 89 Zr-Durvalumab (MEDI4736) PET/CT
- Author
-
Hegi-Johnson, F., primary, Rudd, S., additional, Callahan, J., additional, Wichmann, C., additional, Akhurst, T., additional, Roselt, P., additional, John, T., additional, Donnelly, P., additional, Scott, A., additional, Hanna, G., additional, and MacManus, M., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Imaging immunity in patients with cancer using positron emission tomography
- Author
-
Hegi-Johnson, F, Rudd, S, Hicks, RJ, De Ruysscher, D, Trapani, JA, John, T, Donnelly, P, Blyth, B, Hanna, G, Everitt, S, Roselt, P, MacManus, MP, Hegi-Johnson, F, Rudd, S, Hicks, RJ, De Ruysscher, D, Trapani, JA, John, T, Donnelly, P, Blyth, B, Hanna, G, Everitt, S, Roselt, P, and MacManus, MP
- Abstract
Immune checkpoint inhibitors and related molecules can achieve tumour regression, and even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis. However, it remains unclear why some patients respond to immunotherapy and others do not. PET imaging has the potential to characterise the spatial and temporal heterogeneity of both immunotherapy target molecules and the tumor immune microenvironment, suggesting a tantalising vision of personally-adapted immunomodulatory treatment regimens. Personalised combinations of immunotherapy with local therapies and other systemic therapies, would be informed by immune imaging and subsequently modified in accordance with therapeutically induced immune environmental changes. An ideal PET imaging biomarker would facilitate the choice of initial therapy and would permit sequential imaging in time-frames that could provide actionable information to guide subsequent therapy. Such imaging should provide either prognostic or predictive measures of responsiveness relevant to key immunotherapy types but, most importantly, guide key decisions on initiation, continuation, change or cessation of treatment to reduce the cost and morbidity of treatment while enhancing survival outcomes. We survey the current literature, focusing on clinically relevant immune checkpoint immunotherapies, for which novel PET tracers are being developed, and discuss what steps are needed to make this vision a reality.
- Published
- 2022
14. Please Place Your Seat in the Full Upright Position: A Technical Framework for Landing Upright Radiation Therapy in the 21(st) Century
- Author
-
Hegarty, S, Hardcastle, N, Korte, J, Kron, T, Everitt, S, Rahim, S, Hegi-Johnson, F, Franich, R, Hegarty, S, Hardcastle, N, Korte, J, Kron, T, Everitt, S, Rahim, S, Hegi-Johnson, F, and Franich, R
- Abstract
Delivering radiotherapy to patients in an upright position can allow for increased patient comfort, reduction in normal tissue irradiation, or reduction of machine size and complexity. This paper gives an overview of the requirements for the delivery of contemporary arc and modulated radiation therapy to upright patients. We explore i) patient positioning and immobilization, ii) simulation imaging, iii) treatment planning and iv) online setup and image guidance. Treatment chairs have been designed to reproducibly position seated patients for treatment and can be augmented by several existing immobilisation systems or promising emerging technologies such as soft robotics. There are few solutions for acquiring CT images for upright patients, however, cone beam computed tomography (CBCT) scans of upright patients can be produced using the imaging capabilities of standard Linacs combined with an additional patient rotation device. While these images will require corrections to make them appropriate for treatment planning, several methods indicate the viability of this approach. Treatment planning is largely unchanged apart from translating gantry rotation to patient rotation, allowing for a fixed beam with a patient rotating relative to it. Rotation can be provided by a turntable during treatment delivery. Imaging the patient with the same machinery as used in treatment could be advantageous for online plan adaption. While the current focus is using clinical linacs in existing facilities, developments in this area could also extend to lower-cost and mobile linacs and heavy ion therapy.
- Published
- 2022
15. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
- Author
-
Hegi-Johnson, F, Rudd, SE, Wichmann, C, Akhurst, T, Roselt, P, Trinh, J, John, T, Devereux, L, Donnelly, PS, Hicks, R, Scott, AM, Steinfort, D, Fox, S, Blyth, B, Parakh, S, Hanna, GG, Callahan, J, Burbury, K, MacManus, M, Hegi-Johnson, F, Rudd, SE, Wichmann, C, Akhurst, T, Roselt, P, Trinh, J, John, T, Devereux, L, Donnelly, PS, Hicks, R, Scott, AM, Steinfort, D, Fox, S, Blyth, B, Parakh, S, Hanna, GG, Callahan, J, Burbury, K, and MacManus, M
- Abstract
BACKGROUND: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials. METHODS: The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung cancer (NSCLC). Patients received 60MBq/70 kg 89Zr-durva up to a maximum of 74 MBq, with scan acquisition at days 0, 1, 3 or 5±1 day. Data on (1) Percentage of injected 89Zr-durva dose found in organs of interest (2) Absorbed organ doses (µSv/MBq of administered 89Zr-durva) and (3) whole-body dose expressed as mSv/100MBq of administered dose was collected to characterise biodistribution.The phase 1 study will recruit 20 patients undergoing concurrent chemoradiotherapy for stage III NSCLC. Patients will have 89Zr-durva and FDG-PET/CT before, during and after chemoradiation. In order to establish the feasibility of 89Zr-durva PET/CT for larger multicentre trials, we will collect both imaging and toxicity data. Feasibility will be deemed to have been met if more than 80% of patients are able complete all trial requirements with no significant toxicity. ETHICS AND DISSEMINATION: This phase 0 study has ethics approval (HREC/65450/PMCC 20/100) and is registered on the Australian Clinical Trials Network (ACTRN12621000171819). The protocol, technical and clinical data will be disseminated by conference presentations and publications. Any modifications to the protocol will be formally documented by administrative letters and must be submitted to the approving HREC for review and approval. TRIAL REGISTRATION NUMBER: Australian Clinical Trials Network ACTRN12621000171819.
- Published
- 2022
16. MO-0873 Rapid increase in ctDNA at commencement of curative-intent radiotherapy for NSCLC
- Author
-
MacManus, M., Blyth, B., Martin, O., Plumridge, N., Shaw, M., Hegi-Johnson, F., Siva, S., Banks, O., Kirby, L., Ball, D., and Wong, S.
- Published
- 2023
- Full Text
- View/download PDF
17. OA22.06 Changes in Cognition after Osimertinib, with or without SRS, in EGFRm NSCLC with Brain Metastases: a Pooled Analysis of RCTs
- Author
-
Soon, Y.Y., Lefresne, S., Robledo, K., Nichol, A., Pinkham, M., Sahgal, A., Lee, C.K., Parmar, A., Huang, Y., Doherty, M., Solomon, B., Shultz, D., Tham, I.W.K., Sacher, A., Tey, J.C.S., Leong, C.N., Koh, W.Y., Ang, Y., Low, J., Yong, C., Lim, M.C., Tan, A.P., Soo, R., Ho, C., and Hegi-Johnson, F.
- Published
- 2023
- Full Text
- View/download PDF
18. Part-Time Training: Leveling the Playing Field in Academic Oncology.
- Author
-
Aly F, Bucknell N, Kenny L, and Hegi-Johnson F
- Subjects
- Humans, Radiation Oncology education, Medical Oncology education
- Published
- 2024
- Full Text
- View/download PDF
19. Dose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by 18 F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer.
- Author
-
MacManus MP, Prins E, Xie J, Akhurst T, Hicks RJ, Callahan J, Hegi-Johnson F, Hardcastle N, and Everitt S
- Abstract
Purpose:
18 F-fluorothymidine (FLT) positron emission tomography (PET) enables sensitive imaging of bone marrow (BM) proliferation. Sequential FLT-PET/computed tomography scans before and during chemoradiation therapy (CRT) for non-small cell lung cancer were repurposed to investigate the dose-response effects of radiation on BM proliferation., Methods and Materials: Twenty-six non-small cell lung cancer patients underwent platinum-based CRT to 60 Gy in 30 fractions with FLT-PET/computed tomography scans at baseline, week 2 (20 Gy), and week 4 (40 Gy). FLT uptake in BM was isolated using Medical Image Merge software. Weeks 2 and 4 FLT-PET BM scans were fused with contemporaneous radiation isodose distributions. Relationships between radiation dose and FLT BM uptake (highest standardized uptake values within the volume and visual parameters) were analyzed using generalized linear and restricted cubic spline models. Percentage volumes of total BM without appreciable FLT uptake ("ablated") on weeks 2 and 4 FLT-PET scans were calculated by comparisons with baseline scans., Results: Thoracic FLT uptake was ablated in BM regions exposed to cumulative radiation doses ≥3 Gy by week 2. In all cases, BM FLT's highest standardized uptake values within the volume declined rapidly as the radiation dose increased. BM proliferation significantly decreased by >95% after ≥3 to 4 Gy at 2 weeks and ≥4 to 5 Gy at 4 weeks. The ablated BM volume increased from week 2 to week 4 as BM in the penumbra accumulated radiation dose. The median percentage of total BM ablated was 13.1% (range, 5.6%-20.3%) at 2 weeks and 15.7% (range, 9.2%-24.1%) at 4 weeks. Mean lymphocyte counts fell from a baseline of 2.01 × 109 /L to 0.77 at week 2 and 0.60 at week 4. Lymphocyte decline strongly correlated with the percentage of total BM ablated by week 4 (y = -46 to 1.64x; R2 adj = 0.34; P = .001)., Conclusions: BM ablation associated with low-dose radiation exposure during CRT correlated significantly with lower week 4 lymphocyte counts. BM is a potential organ at risk, and reducing the BM volume exposed to ≥3 Gy may help preserve lymphocytes, which is essential for effective adjuvant immunotherapy., (Copyright © 2024 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
20. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape.
- Author
-
Weller M, Remon J, Rieken S, Vollmuth P, Ahn MJ, Minniti G, Le Rhun E, Westphal M, Brastianos PK, Soo RA, Kirkpatrick JP, Goldberg SB, Öhrling K, Hegi-Johnson F, and Hendriks LEL
- Abstract
Up to 40% of patients with non-small cell lung cancer (NSCLC) develop central nervous system (CNS) metastases. Current treatments for this subgroup of patients with advanced NSCLC include local therapies (surgery, stereotactic radiosurgery, and, less frequently, whole-brain radiotherapy), targeted therapies for oncogene-addicted NSCLC (small molecules, such as tyrosine kinase inhibitors, and antibody-drug conjugates), and immune checkpoint inhibitors (as monotherapy or combination therapy), with multiple new drugs in development. However, confirming the intracranial activity of these treatments has proven to be challenging, given that most lung cancer clinical trials exclude patients with untreated and/or progressing CNS metastases, or do not include prespecified CNS-related endpoints. Here we review progress in the treatment of patients with CNS metastases originating from NSCLC, examining local treatment options, systemic therapies, and multimodal therapeutic strategies. We also consider challenges regarding assessment of treatment response and provide thoughts around future directions for managing CNS disease in patients with advanced NSCLC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET Collaboration.
- Author
-
Robledo KP, Lefresne S, Soon YY, Sahgal A, Pinkham MB, Nichol A, Soo RA, Parmar A, Hegi-Johnson F, Doherty M, Solomon BJ, Shultz DB, Tham IW, Sacher AG, Tey J, Leong CN, Koh WY, Huang Y, Ang YLE, Low J, Yong C, Lim MC, Tan AP, Lee CK, and Ho C
- Subjects
- Humans, Antineoplastic Agents therapeutic use, Combined Modality Therapy, Indoles, Meta-Analysis as Topic, Mutation, Prospective Studies, Pyrimidines, Randomized Controlled Trials as Topic, Research Design, Acrylamides therapeutic use, Aniline Compounds therapeutic use, Brain Neoplasms secondary, Brain Neoplasms genetics, Brain Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung secondary, ErbB Receptors genetics, Lung Neoplasms genetics, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Radiosurgery methods, Systematic Reviews as Topic
- Abstract
Background: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor ( EGFR ) gene are a heterogeneous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer-generation targeted therapies in the central nervous system. We present a protocol for an individual patient data (IPD) prospective meta-analysis to evaluate whether the addition of stereotactic radiosurgery (SRS) before osimertinib treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant question that will inform practice., Methods: Randomised controlled trials will be eligible if they include participants with BM arising from EGFR- mutant NSCLC and suitable to receive osimertinib both in the first-line and second-line settings (P); comparisons of SRS followed by osimertinib versus osimertinib alone (I, C) and intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the WHO's International Clinical Trials Registry Platform's Search Portal will be undertaken. An IPD meta-analysis will be performed using methodologies recommended by the Cochrane Collaboration. The primary outcome is intracranial progression-free survival, as determined by response assessment in neuro-oncology-BM criteria. Secondary outcomes include overall survival, time to whole brain radiotherapy, quality of life, and adverse events of special interest. Effect differences will be explored among prespecified subgroups., Ethics and Dissemination: Approved by each trial's ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases., Prospero Registration: CRD42022330532., Competing Interests: Competing interests: SL: research funding and honoraria from AstraZeneca. YYS: honoraria from AstraZeneca and Janssen. AGS: research grants (institution) from Elekta AB, Varian, Seagen and BrainLAB; consulting fees from Varian, Elekta (Gamma Knife Icon), BrainLAB, Merck, Abbvie and Roche; honoraria from AstraZeneca, Elekta AB, Varian, BrainLAB, Accuray and Seagen. MBP: speaker fees from AZ, BMS, MSD and Roche. AN: research grants from Varian Medical Systems. RAS: advisory board with Amgen, Astra-Zeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma Biotechnology, Roche, Taiho, Takeda, Thermo Fisher and Yuhan Corporation; research grant from Astra-Zeneca and Boehringer Ingelheim. FHJ: clinical trial funding, received honoraria and participated in advisory boards for Astra Zeneca; received payments and honoraria from BeiGene and MSD for lectures and presentations; supported by the Peter Mac Foundation and the Victorian Cancer Agency. BJS: advisory board/honoraria from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Merck, Bristol Mysers Squibb, Janssen, Amgen and Eli Lilly. IWKT: honorarium from Elekta and MSD. CH: advisory boards with Abbvie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Jazz, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda; research grants from AstraZeneca, EMD Serono and Roche. CKL: advisory board with Amgen, Astra Zeneca, GSK, Merck KGA, Norvatis, Pfizer, Roche, Takeda, Boehringer-Ingelheim and Yuhan; research funding (institution) from Astra Zeneca, Roche, Merck KGA and Amgen. KPR, AP, MD, DBS, AGS, JT, CNL, WYK, YH, YLEA, JL, CY, MCL and APT have no competing interests. CH, SL, FHJ, CKL, YYS, RAS and IWKT are study chairs on the included trials., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
22. Response to COVID-19 vaccination imaged by PD-L1 PET scanning.
- Author
-
MacManus MP, Akhurst T, Lewin SR, and Hegi-Johnson F
- Abstract
Background: During a phase 0 clinical trial of an investigational programmed cell death ligand-1 (PD-L1) PET tracer in patients with non-small cell lung cancer (NSCLC), three patients received booster doses of COVID-19 vaccines before PD-L1 imaging., Methods: Five patients underwent whole-body PET/CT imaging with a novel PD-L1 tracer, constructed by attaching
89 Zr to the anti PD-L1 antibody durvalumab. Intramuscular (deltoid) booster doses of mRNA BNT162b2 COVID-19 mRNA vaccine were coincidentally given to three patients in the month before PD-L1 tracer injection., Results: Two recently-vaccinated patients, in remission of NSCLC and receiving non-immunosuppressive cancer therapies (immunotherapy and tyrosine kinase inhibitor respectively), showed increasing PD-L1 tracer uptake in ipsilateral axillary lymph nodes. No asymmetric nodal uptake was seen in a third recently-vaccinated patient who was receiving immunosuppressive chemotherapy, or in two patients not recently-vaccinated., Conclusion: Immune response to mRNA BNT162b2 vaccination may involve regulation by PD-L1 positive immune cells in local draining lymph nodes in immunocompetent patients., Trial Registration: This trial was registered with the Australian New Zealand Clinical Trials Registry. Registration number ACTRN12621000171819. Date of Trial Registration 8/2/2021. Date of enrolment of 1st patient 11/4/2021. URL of trial registry record: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12621000171819 ., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
23. Evaluating a Remotely Delivered Cardio-Oncology Rehabilitation Intervention for Patients With Breast Cancer (REMOTE-COR-B): Protocol for a Single-Arm Feasibility Trial.
- Author
-
Short CE, Rawstorn JC, Jones TL, Edbrooke L, Hayes SC, Maddison R, Nightingale S, Ismail H, De Boer R, Hegi-Johnson F, Sverdlov AL, Bell R, Halligan I, and Denehy L
- Abstract
Background: Exercise rehabilitation is a promising strategy for reducing cardiovascular disease risk among patients with breast cancer. However, the evidence is primarily derived from programs based at exercise centers with in-person supervised delivery. Conversely, most patients report a preference for home-based rehabilitation. As such, there is a clear need to explore strategies that can provide real-time supervision and coaching while addressing consumer preferences. Evidence from cardiac rehabilitation has demonstrated the noninferiority of a smartphone-based telerehabilitation approach (REMOTE-CR) to improve cardiorespiratory fitness in people with cardiovascular disease compared to a center-based program., Objective: This study aims to assess the feasibility, safety, and preliminary efficacy of the REMOTE-CR program adapted for patients with breast cancer at risk of cardiotoxicity (REMOTE-COR-B). We will also assess the satisfaction and usability of REMOTE-COR-B., Methods: We will conduct a single-arm feasibility study of the REMOTE-COR-B program among patients with stage I-III breast cancer who are at risk of cardiotoxicity (taking treatment type and dose, as well as other common cardiovascular disease risk factors into account) and who are within 24 months of completing primary definitive treatment. Participants (target sample size of 40) will receive an 8-week smartphone-based telerehabilitation exercise program involving remotely delivered real-time supervision and behavior change support. The platform comprises a smartphone and wearable heart rate monitor, as well as a custom-built smartphone app and web application. Participants will be able to attend remotely monitored exercise sessions during set operating hours each week, scheduled in both the morning and evening. Adherence is the primary outcome of the trial, assessed through the number of remotely monitored exercise sessions attended compared to the trial target (ie, 3 sessions per week). Secondary outcomes include additional trial feasibility indicators (eg, recruitment and retention), safety, satisfaction, and usability, and objective and patient-reported efficacy outcomes (cardiovascular fitness, quality of life, fatigue, self-reported exercise, self-efficacy, habit strength, and motivation). Adherence, feasibility, and safety outcomes will be assessed during the intervention period; intervention satisfaction and usability will be assessed post intervention; and objective and patient-reported efficacy outcomes will be assessed at baseline, post intervention (2-month postbaseline assessment), and at follow-up (5-month postbaseline assessment)., Results: Recruitment for this trial commenced in March 2023, and 7 participants had been recruited as of the submission of the manuscript. The estimated completion date for the project is October 2024, with results expected to be published in mid-2025., Conclusions: The REMOTE-COR-B intervention is a novel and promising approach to providing exercise therapy to patients with breast cancer at risk of cardiotoxicity who have unique needs and heightened safety risks. This project will provide important information on the extent to which this approach is satisfactory to patients with breast cancer, safe, and potentially effective, which is necessary before larger-scale research or clinical projects., Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12621001557820; www.anzctr.org.au/ACTRN12621001557820.aspx., International Registered Report Identifier (irrid): DERR1-10.2196/53301., (©Camille E Short, Jonathan C Rawstorn, Tamara L Jones, Lara Edbrooke, Sandra C Hayes, Ralph Maddison, Sophie Nightingale, Hilmy Ismail, Richard De Boer, Fiona Hegi-Johnson, Aaron L Sverdlov, Robyn Bell, Irene Halligan, Linda Denehy. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 05.04.2024.)
- Published
- 2024
- Full Text
- View/download PDF
24. The impact of pre-treatment smoking status on survival after chemoradiotherapy for locally advanced non-small-cell lung cancer.
- Author
-
Wallace ND, Alexander M, Xie J, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Officer A, and MacManus M
- Subjects
- Humans, Retrospective Studies, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Smoking adverse effects, Chemoradiotherapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Smoking is a risk factor for the development of lung cancer and reduces life expectancy within the general population. Retrospective studies suggest that non-smokers have better outcomes after treatment for lung cancer. We used a prospective database to investigate relationships between pre-treatment smoking status and survival for a cohort of patients with stage III non-small-cell lung cancer (NSCLC) treated with curative-intent concurrent chemoradiotherapy (CRT)., Methods: All patients treated with CRT for stage III NSCLC at a major metropolitan cancer centre were prospectively registered to a database. A detailed smoking history was routinely obtained at baseline. Kaplan-Meier statistics were used to assess overall survival and progression-free survival in never versus former versus current smokers., Results: Median overall survival for 265 eligible patients was 2.21 years (95 % Confidence Interval 1.78, 2.84). It was 5.5 years (95 % CI 2.1, not reached) for 25 never-smokers versus 1.9 years (95 % CI 1.5, 2.7) for 182 former smokers and 2.2 years (95 % CI 1.3, 2.7) for 58 current smokers. Hazard ratio for death was 2.43 (95 % CI 1.32-4.50) for former smokers and 2.75 (95 % CI 1.40, 5.40) for current smokers, p = 0.006. Actionable tumour mutations (EGFR, ALK, ROS1) were present in more never smokers (14/25) than former (9/182) or current (3/58) smokers. TKI use was also higher in never smokers but this was not significantly associated with superior survival (Hazard ratio 0.71, 95 % CI 0.41, 1.26)., Conclusions: Never smokers have substantially better overall survival than former or current smokers after undergoing CRT for NSCLC., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
- Author
-
Kato T, Casarini I, Cobo M, Faivre-Finn C, Hegi-Johnson F, Lu S, Özgüroğlu M, and Ramalingam SS
- Subjects
- Humans, Retrospective Studies, Protein Kinase Inhibitors pharmacology, ErbB Receptors genetics, Mutation genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Epidermal growth factor receptor (EGFR) mutations are detected in up to one third of patients with unresectable stage III non-small cell lung cancer (NSCLC). The current standard of care for unresectable stage III NSCLC is consolidation durvalumab for patients who have not progressed following concurrent chemoradiotherapy (the 'PACIFIC regimen'). However, the benefit of immunotherapy, specifically in patients with EGFR mutation-positive (EGFRm) tumors, is not well characterized, and this treatment approach is not recommended in these patients, based on a recent ESMO consensus statement. EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have demonstrated significant improvements in patient outcomes in EGFRm metastatic NSCLC. The benefits of these agents have also translated to patients with EGFRm early-stage resectable disease as adjuvant therapy. The role of EGFR-TKIs has yet to be prospectively characterized in the unresectable setting. Preliminary efficacy signals for EGFR-TKIs in unresectable EGFRm stage III NSCLC have been reported from a limited number of subgroup and retrospective studies. Several clinical trials are ongoing assessing the safety and efficacy of EGFR-TKIs in this patient population. Here, we review the current management of unresectable EGFRm stage III NSCLC. We outline the rationale for investigating EGFR-TKI strategies in this setting and discuss ongoing studies. Finally, we discuss the evidence gaps and future challenges for treating patients with unresectable EGFRm stage III NSCLC., Competing Interests: Declaration of competing interest Terufumi Kato reports consulting/advisory roles: AstraZeneca, BeiGene, Daiichi-Sankyo, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer; honoraria: Amgen Inc., AstraZeneca, BeiGene, Boehringer Ingelheim, Chugai Pharmaceuticals Co., Ltd., Daiichi-Sankyo, Eli Lilly and Company, GlaxoSmithKline, Janssen, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical Co., Ltd., Pfizer, Taiho Pharmaceutical, Takeda; employment (spouse): Eli Lilly and company; research support (to institution): AbbVie Inc., Amgen Inc., AstraZeneca, BeiGene, Blueprint Medicines, Chugai Pharmaceutical Co., Ltd., Daiichi-Sankyo, Eli Lilly and Company, HaiHe Biopharma, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Takeda, Turning Point Therapeutics Inc. Ignacio Casarini reports local principal investigator role: AstraZeneca, Bristol-Myers Squibb, Exelixis, Lilly, Merck Sharp & Dohme, Novartis, Roche (non-financial and for institution); principal investigator role for multiple clinical studies: AstraZeneca, Bristol-Myers Squibb, Exelixis, Lilly, Merck Sharp & Dohme, Novartis; principal investigator role for one clinical study: Roche. Corinne Faivre-Finn reports research funding: AstraZeneca, and Elekta; travel expenses: AstraZeneca, Elekta, Peter MacCallum Cancer Centre, and CF-F’s institution; and uncompensated relationships: AstraZeneca, Elekta, and Merck Sharpe & Dohme. CF-F is supported by a grant from the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre. Fiona Hegi-Johnson reports research funding: AstraZeneca; honoraria: AstraZeneca; payment or honoraria for lectures and presentations: BeiGene, Merck Sharpe & Dohme. Participation on an advisory board: AstraZeneca. FH-J is supported by the Victorian Cancer Agency. Shun Lu reports consulting/advisory roles: AstraZeneca, Boehringer Ingelheim, GenomiCare Biotechnology, Hutchison MediPharma Ltd., Pfizer, prIME Oncology, Roche, Simcere Pharmaceutical Group, Yuhan, Zai Lab; speaker’s bureau: AstraZeneca, Hansoh Pharmaceutical Group Co. Ltd., Hengrui Pharmaceuticals Company Ltd., Roche; research funding (to institution): AstraZeneca, BeiGene, Bristol-Myers Squibb, Hansoh Pharmaceutical Group Co. Ltd., Hengrui Pharmaceuticals Company Ltd., Hutchison MediPharma Ltd., Lilly Suzhou Pharmaceutical Co. Ltd., Roche. Mustafa Özgüroğlu reports consulting/advisory roles: Astellas (to self and institution), Janssen, Sanofi; honoraria: Astellas (to self and institution), Janssen, Novartis, Roche, Sanofi. Suresh S. Ramalingam reports consulting/advisory roles: Amgen Inc., AstraZeneca, Bristol-Myers Squibb, Genentech, Merck & Co. Inc., Takeda Inc., Tesaro; research funding: Amgen Inc., Advaxis Inc., AstraZeneca, Bristol-Myers Squibb, Genmab, Merck & Co. Inc., Takeda, Tesaro Inc. Manuel Cobo declares no conflicts of interest., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
- Author
-
Ahn J, Yeghiaian-Alvandi R, Hegi-Johnson F, Browne LH, Graham PH, Chin Y, Gee H, Vinod S, Ludbrook J, Last A, Dwyer P, Ong A, Aherne N, Azzi M, and Hau E
- Subjects
- Humans, Quality of Life, Prospective Studies, Carbon Monoxide, Lung, Dyspnea etiology, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
- Abstract
Purpose: The aim of this study was to report pulmonary function tests (PFTs) and clinician-reported and patient-reported quality-of-life (QoL) outcomes on a cohort of patients with non-small cell lung cancer (NSCLC) treated with SABR., Methods and Materials: A total of 119 patients with NSCLC were treated with SABR in the prospective cohort SSBROC study of patients with T1-T2N0M0 NSCLC. PFTs and QoL measures were obtained at baseline pretreatment and at 6-month intervals. Here we report on the 6- to 18-month time points. Analysis of covariance (ANCOVA) methods adjusting for baseline analyzed potential predictors on outcomes of PFTs and patient-reported dyspnea at 18 months., Results: The only statistically significant decline in PFTs was seen in forced expiratory volume in 1 second (FEV
1 ) at 18 months post-SABR, with a decline of -0.11 L (P = .0087; 95% CI, -0.18 to -0.02). Of potential predictors of decline, only a 1-unit increase in smoking pack-years resulted in a -0.12 change in diffusing capacity for carbon monoxide (P = .026; 95% CI, -0.02 to -0.23) and a 0.003 decrease in FEV1 (P = .026; 95% CI, -0.006 to -0.0004). For patient-reported outcomes, statistically significant worsening in both the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30 Version 3) and the lung module (QLQ-LC13) dyspnea scores occurred at the 18-month time point, but not earlier. No potential predictors of worsening dyspnea were statistically significant. There was no statistically significant decline in clinician-reported outcomes or global QoL scores., Conclusions: We found a statistically significant decline in FEV1 at 18 months posttreatment. Smoking pack-years was a predictor for decline in diffusing capacity for carbon monoxide and FEV1 at 18 months. Worsening of patient-reported dyspnea scores was observed, consistent with the expected progression of lung comorbid disease., (Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
27. PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
- Author
-
Hegi-Johnson F, Rudd SE, Wichmann CW, Akhurst T, Roselt P, Sursock S, Trinh J, John T, Devereux L, Donnelly PS, Hicks RJ, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, and MacManus M
- Subjects
- Humans, B7-H1 Antigen, Positron-Emission Tomography methods, Positron Emission Tomography Computed Tomography methods, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Lung Neoplasms diagnostic imaging
- Published
- 2023
- Full Text
- View/download PDF
28. Early circulating tumor DNA dynamics at the commencement of curative-intent radiotherapy or chemoradiotherapy for NSCLC.
- Author
-
MacManus M, Kirby L, Blyth B, Banks O, Martin OA, Yeung MM, Plumridge N, Shaw M, Hegi-Johnson F, Siva S, Ball D, and Wong SQ
- Abstract
Background: The kinetics of circulating tumor DNA (ctDNA) release following commencement of radiotherapy or chemoradiotherapy may reflect early tumour cell killing. We hypothesised that an increase in ctDNA may be observed after the first fraction of radiotherapy and that this could have clinical significance., Materials and Methods: ctDNA analysis was performed as part of a prospective, observational clinical biomarker study of non-small cell lung cancer (NSCLC) patients, treated with curative-intent radiotherapy or chemoradiotherapy. Blood was collected at predefined intervals before, during (including 24 h after fraction 1 of radiotherapy) and after radiotherapy/chemoradiotherapy. Mutation-specific droplet digital PCR assays used to track ctDNA levels during and after treatment., Results: Sequential ctDNA results are available for 14 patients with known tumor-based mutations, including in EGFR , KRAS and TP53 , with a median follow-up of 723 days (range 152 to 1110). Treatments delivered were fractionated radiotherapy/chemoradiotherapy, in 2-2.75 Gy fractions (n = 12), or stereotactic ablative body radiotherapy (SABR, n = 2). An increase in ctDNA was observed after fraction 1 in 3/12 patients treated with fractionated radiotherapy with a complete set of results, including in 2 cases where ctDNA was initially undetectable. Neither SABR patient had detectable ctDNA immediately before or after radiotherapy, but one of these later relapsed systemically with a high detected ctDNA concentration., Conclusions: A rapid increase in ctDNA levels was observed after one fraction of fractionated radiotherapy in three cases. Further molecular characterization will be required to understand if a "spike" in ctDNA levels could represent rapid initial tumor cell destruction and could have clinical value as a surrogate for early treatment response and/or as a means of enriching ctDNA for mutational profiling., Competing Interests: FH-J has clinical trial funding, has received honoraria and participated in advisory boards for Astra Zeneca. She has received payments and honoraria from BeiGene and MSD for lectures and presentations. She receives clinical trial support from Telix Pharmaceuticals. The authors otherwise have no disclosures to report., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
29. Automated radiosynthesis of [ 89 Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.
- Author
-
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, Blyth B, Van Zuylekom J, Rigopoulos A, Burvenich IJG, Morandeau L, Mohamed S, Nowak AK, Hegi-Johnson F, MacManus M, and Scott AM
- Subjects
- Humans, Animals, Mice, HEK293 Cells, Antibodies, Monoclonal, Positron-Emission Tomography methods, Radiopharmaceuticals, Zirconium, B7-H1 Antigen metabolism, Neoplasms
- Abstract
Objectives:
89 Zr-labelled proteins are gaining importance in clinical research in a variety of diseases. To date, no clinical study has been reported that utilizes an automated approach for radiosynthesis of89 Zr-labelled radiopharmaceuticals. We aim to develop an automated method for the clinical production of89 Zr-labelled proteins and apply this method to Durvalumab, a monoclonal antibody targeting PD-L1 immune-checkpoint protein. PD-L1 expression is poorly understood and can be up-regulated over the course of chemo- and radiotherapy treatment. The ImmunoPET multicentre study aims to examine the dynamics of PD-L1 expression via89 Zr-Durvalumab PET imaging before, during, and after chemoradiotherapy. The developed automated technique will enable reproducible clinical production of [89 Zr]Zr-DFOSq-Durvalumab for this study at three different sites., Methods: Conjugation of Durvalumab to H3 DFOSqOEt was optimized for optimal chelator-to-antibody ratio. Automated radiolabelling of H3 DFOSq-Durvalumab with zirconium-89 was optimized on the disposable cassette based iPHASE technologies MultiSyn radiosynthesizer using a modified cassette. Activity losses were tracked using a dose calibrator and minimized by optimizing fluid transfers, reaction buffer, antibody formulation additives and pH. The biological profile of the radiolabelled antibody was confirmed in vivo in PD-L1+ (HCC827) and PD-L1- (A549) murine xenografts. Clinical process validation and quality control were performed at three separate study sites to satisfy clinical release criteria., Results: H3 DFOSq-Durvalumab with an average CAR of 3.02 was obtained. Radiolabelling kinetics in succinate (20 mM, pH 6) were significantly faster when compared to HEPES (0.5 M, pH 7.2) with >90 % conversion observed after 15 min. Residual radioactivity in the89 Zr isotope vial was reduced from 24 % to 0.44 % ± 0.18 % (n = 7) and losses in the reactor vial were reduced from 36 % ± 6 % (n = 4) to 0.82 % ± 0.75 % (n = 4) by including a surfactant in the reaction and formulation buffers. Overall process yield was 75 % ± 6 % (n = 5) and process time was 40 min. Typically, 165 MBq of [89 Zr]Zr-DFOSq-Durvalumab with an apparent specific activity of 315 MBq/mg ± 34 MBq/mg (EOS) was obtained in a volume of 3.0 mL. At end-of-synthesis (EOS), radiochemical purity and protein integrity were always >99 % and >96 %, respectively, and dropped to 98 % and 65 % after incubation in human serum for 7 days at 37 °C. Immunoreactive fraction in HEK293/PD-L1 cells was 83.3 ± 9.0 (EOS). Preclinical in vivo data at 144 h p.i. showed excellent SUVmax in PD-L1+ tumour (8.32 ± 0.59) with a tumour-background ratio of 17.17 ± 3.96. [89 Zr]Zr-DFOSq-Durvalumab passed all clinical release criteria at each study site and was deemed suitable for administration in a multicentre imaging trial., Conclusion: Fully automated production of [89 Zr]Zr-DFOSq-Durvalumab for clinical use was achieved with minimal exposure to the operator. The cassette-based approach allows for consecutive productions on the same day and offers an alternative to currently used manual protocols. The method should be broadly applicable to other proteins and has the potential for clinical impact considering the growing number of clinical trials investigating89 Zr-labelled antibodies., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SP is the director of iPHASE technologies Pty Ltd. (Melbourne, Australia). AN receives institutional funding from AstraZeneca Pty Ltd. (Cambridge, UK) for clinical trials and translational science unrelated to this work. PSD and SER are listed as inventors on intellectual property relating to the use of DFOSq that has been licensed from the University of Melbourne to Telix Pharmaceuticals. This work was supported by AstraZeneca Pty Ltd. (Cambridge, UK) and Telix Pharmaceuticals Limited (Melbourne, Australia)., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
30. Editorial: Factors that impact the survival of non-small cell lung cancer.
- Author
-
Hegi-Johnson F and Higgins KA
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
31. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89 Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
- Author
-
Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, and MacManus M
- Subjects
- Humans, Australia, B7-H1 Antigen, Chemoradiotherapy, Immunotherapy, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography methods, Tissue Distribution, Carcinoma, Non-Small-Cell Lung therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms therapy, Lung Neoplasms drug therapy
- Abstract
Background: ImmunoPET is a multicentre, single arm, phase 0-1 study that aims to establish if
89 Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials., Methods: The phase 0 study recruited 5 PD-L1+ patients with metastatic non-small cell lung cancer (NSCLC). Patients received 60MBq/70 kg89 Zr-durva up to a maximum of 74 MBq, with scan acquisition at days 0, 1, 3 or 5±1 day. Data on (1) Percentage of injected89 Zr-durva dose found in organs of interest (2) Absorbed organ doses (µSv/MBq of administered89 Zr-durva) and (3) whole-body dose expressed as mSv/100MBq of administered dose was collected to characterise biodistribution.The phase 1 study will recruit 20 patients undergoing concurrent chemoradiotherapy for stage III NSCLC. Patients will have89 Zr-durva and FDG-PET/CT before, during and after chemoradiation. In order to establish the feasibility of89 Zr-durva PET/CT for larger multicentre trials, we will collect both imaging and toxicity data. Feasibility will be deemed to have been met if more than 80% of patients are able complete all trial requirements with no significant toxicity., Ethics and Dissemination: This phase 0 study has ethics approval (HREC/65450/PMCC 20/100) and is registered on the Australian Clinical Trials Network (ACTRN12621000171819). The protocol, technical and clinical data will be disseminated by conference presentations and publications. Any modifications to the protocol will be formally documented by administrative letters and must be submitted to the approving HREC for review and approval., Trial Registration Number: Australian Clinical Trials Network ACTRN12621000171819., Competing Interests: Competing interests: FH-J has clinical trial funding, has received honoraria and participated in advisory boards for Astra Zeneca. She has received payments and honoria from BeiGene and MSD for lectures and presentations. Her work is supported by the Peter Mac Foundation and the Victorian Cancer Agency. SER and PSD are inventors on intellectual property relating to the use of DFOSq that have been licensed from the University of Melbourne to Telix Pharmaceuticals. TJ has received payments and honoraria from BMS and Astra Zeneca for lectures and presentations, and sits on Data Safety and Monitoring Boards or Advisory boards for Roche, BMS, Astra Zeneca, Novartis, Amgen, Puma, MSD and Merck. SF has received payments and honoraria from Astra Zeneca, Roche, Amgen, Novartis, Bayer, GSK, BMS, MSD and Janssen for lectures and presentations. KB has received payments and honoraria from Bayer and Abbvie for lectures and presentations and participates on Data Safety and Monitoring boards for Novartis., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2022
- Full Text
- View/download PDF
32. Imaging immunity in patients with cancer using positron emission tomography.
- Author
-
Hegi-Johnson F, Rudd S, Hicks RJ, De Ruysscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, and MacManus MP
- Abstract
Immune checkpoint inhibitors and related molecules can achieve tumour regression, and even prolonged survival, for a subset of cancer patients with an otherwise dire prognosis. However, it remains unclear why some patients respond to immunotherapy and others do not. PET imaging has the potential to characterise the spatial and temporal heterogeneity of both immunotherapy target molecules and the tumor immune microenvironment, suggesting a tantalising vision of personally-adapted immunomodulatory treatment regimens. Personalised combinations of immunotherapy with local therapies and other systemic therapies, would be informed by immune imaging and subsequently modified in accordance with therapeutically induced immune environmental changes. An ideal PET imaging biomarker would facilitate the choice of initial therapy and would permit sequential imaging in time-frames that could provide actionable information to guide subsequent therapy. Such imaging should provide either prognostic or predictive measures of responsiveness relevant to key immunotherapy types but, most importantly, guide key decisions on initiation, continuation, change or cessation of treatment to reduce the cost and morbidity of treatment while enhancing survival outcomes. We survey the current literature, focusing on clinically relevant immune checkpoint immunotherapies, for which novel PET tracers are being developed, and discuss what steps are needed to make this vision a reality., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
33. Please Place Your Seat in the Full Upright Position: A Technical Framework for Landing Upright Radiation Therapy in the 21 st Century.
- Author
-
Hegarty S, Hardcastle N, Korte J, Kron T, Everitt S, Rahim S, Hegi-Johnson F, and Franich R
- Abstract
Delivering radiotherapy to patients in an upright position can allow for increased patient comfort, reduction in normal tissue irradiation, or reduction of machine size and complexity. This paper gives an overview of the requirements for the delivery of contemporary arc and modulated radiation therapy to upright patients. We explore i) patient positioning and immobilization, ii) simulation imaging, iii) treatment planning and iv) online setup and image guidance. Treatment chairs have been designed to reproducibly position seated patients for treatment and can be augmented by several existing immobilisation systems or promising emerging technologies such as soft robotics. There are few solutions for acquiring CT images for upright patients, however, cone beam computed tomography (CBCT) scans of upright patients can be produced using the imaging capabilities of standard Linacs combined with an additional patient rotation device. While these images will require corrections to make them appropriate for treatment planning, several methods indicate the viability of this approach. Treatment planning is largely unchanged apart from translating gantry rotation to patient rotation, allowing for a fixed beam with a patient rotating relative to it. Rotation can be provided by a turntable during treatment delivery. Imaging the patient with the same machinery as used in treatment could be advantageous for online plan adaption. While the current focus is using clinical linacs in existing facilities, developments in this area could also extend to lower-cost and mobile linacs and heavy ion therapy., Competing Interests: NH and TK receive collaborative research funding from Varian Medical Systems and Reflexion Medical for unrelated projects. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Hegarty, Hardcastle, Korte, Kron, Everitt, Rahim, Hegi-Johnson and Franich.)
- Published
- 2022
- Full Text
- View/download PDF
34. Overcoming immunotherapy resistance in NSCLC.
- Author
-
MacManus M and Hegi-Johnson F
- Subjects
- Humans, Immunotherapy adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Competing Interests: FH-J has received clinical trial funding from AstraZeneca. MM declares no competing interests.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.